Skip to main content

Advertisement

Table 4 Second-line drug resistance by study site and treatment history

From: The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance

Study site Treatment history Second-line drug resistance amongst MDR Total MDR with second-line DST done Pre-XDR drug resistance profiles of MDR isolates
Susceptible Pre-XDR Fluoroquinolones Injectables
OFX KAN CAP KAN/CAP
N % n % n % n % n % n %
Burkina Faso All   1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
New 0
Retreatment 1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
The Gambia All   9 (75) 3 (25) 12 0 (0) 0 (0) 2 (17) 1 (8)
New 0 (0) 0 (0) 0 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 9 (75) 3 (25) 12 0 (0) 0 (0) 2 (17) 1 (8)
Ghana All   20 (61) 13 (39) 33 3 (9) 2 (6) 7 (21) 1 (3)
New 0 (0) 2 (100) 2 0 (0) 2 (100) 0 (0) 0 (0)
Retreatment 20 (65) 11 (35) 31 3 (10) 0 (0) 7 (23) 1 (3)
Guinea-Bissau All   1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
New 1 (100) 0 (0) 1 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 0
Mali All   30 (79) 8 (21) 38 1 (3) 1 (3) 5 (13) 1 (3)
New 5 (100) 0 (0) 5 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 25 (76) 8 (24) 33 1 (3) 1 (3) 5 (16) 1 (3)
Nigeria/Ibadan All   13 (76) 4 (23) 17 2 (12) 0 (0) 2 (12) 0 (0)
New 0 (0) 0 (0) 0 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 13 (76) 4 (23) 17 2 (12) 0 (0) 2 (12) 0 (0)
Nigeria/Lagos All   59 (91) 6 (9) 65 6 (9) 0 (0) 0 (0) 0 (0)
New 8 (100) 0 (0) 8 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 51 (89) 6 (11) 57 6 (10) 0 (0) 0 (0) 0 (0)
Senegal All   5 (100) 0 (0) 5 0 (0) 0 (0) 0 (0) 0 (0)
New 2 (100) 0 (0) 2 0 (0) 0 (0) 0 (0) 0 (0)
Retreatment 3 (100) 0 (0) 3 0 (0) 0 (0) 0 (0) 0 (0)
Togo All   20 (74) 7 (26) 27 1 (4) 1 (4) 3 (11) 2 (7)
New 2 (40) 3 (60) 5 1 (20) 0 (0) 1 (20) 1 (20)
Retreatment 18 (82) 4 (18) 22 0 (0) 1 (4) 2 (9) 1 (4)
All study sites All   158 (79) 41 (21) 199 12 (6) 4 (2) 19 (9) 6 (3)
New 18 (78) 5 (22) 23 1 (4) 2 (9) 1 (4) 1 (4)
Retreatment 140 (80) 36 (20) 176 11 (6) 2 (1) 18 (10) 5 (3)
  1. No extensively drug-resistant isolates (XDR) were found in the survey. The proportion of pre-XDR within the population of MDR isolates is displayed as well as a detailed description of pre-XDR isolates and their resistance patterns, stratified by mono-resistance to ofloxacin (OFX), kanamycin (KAN) and capreomycin (CAP) and the combination of the latter two (KAN/CAP)